Navigation Links
Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
Date:1/20/2009

NEW YORK, Jan. 20 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE-A: MGT), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, which assists radiologists in the early detection of disease, announces that it has received a request for Additional Information (AI) letter from the U.S. Food and Drug Administration (FDA). This request is in regard to the 510(k) pre-market notification for the ColonCAD API 3.1 product. The FDA has requested clarification of the intended use of the product. Medicsight is collating the information required, will continue discussions with the FDA and will provide a response to the agency in due course.

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerized tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyze potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualization workstations of several industry-leading imaging equipment partners.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.


'/>"/>
SOURCE MGT Capital Investments, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
2. Medicsight Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008
3. Medicsight ColonCAD Technology Successfully Identified Cancer in 100% of Patients Included in Data Presented at ESGAR 2008
4. Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser
5. MGT Capital Investments, Inc. is Delighted with the Announcement of Medicsights Commercial Agreement with Toshiba PACS Division
6. Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
7. CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
8. Allscripts Receives 2008 CCHIT Certification
9. Nu Skin Enterprises Receives Broader Direct Selling Authorization in China
10. Avalon Laboratories receives FDA and European clearances to market 3 catheter devices
11. Avalon Laboratories receives FDA and European clearances to market three catheter devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , ... May 27, 2016 , ... More than a ... it is not surprising that bariatric surgery has received increased attention in recent years, ... Of course, when it comes to weight loss, most people are familiar with the ...
(Date:5/27/2016)... ... 27, 2016 , ... With over 60 percent of acute stroke survivors being ... product to aid in the rehabilitation process has steadily increased. Ekso Bionics had been ... hemiplegia due to stroke. , Ekso Bionics has now received clearance from the U.S. ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... ... 26, 2016 , ... Connor Sports, through its Connor Cares initiative, ... Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame ... in all forms and levels of the game, Connor Sports has committed to a ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... SAN FRANCISCO , May 27, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, Neurology and ... Commissiong will be presenting at two upcoming investor conferences: ... Conference Center, 730 Third Avenue, New York City ... at 3:00pm Marcum MicroCap Conference   ...
(Date:5/26/2016)... May 26, 2016 A key ... is the emergence of new treatments. Cardax, a development ... osteoarthritis treatment. The therapy is expected to fulfil large ... UK is conducting studies to develop new treatments for ... the genes involved in osteoarthritis are being investigated, and ...
Breaking Medicine Technology: